- Home
- HRMY
as 05-30-2025 4:00pm EST
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | PLYMOUTH MEETING |
| Market Cap: | 2.0B | IPO Year: | 2020 |
| Target Price: | $53.38 | AVG Volume (30 days): | 751.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.62 | EPS Growth: | 13.13 |
| 52 Week Low/High: | $26.47 - $41.61 | Next Earning Date: | 05-06-2025 |
| Revenue: | $744,852,000 | Revenue Growth: | 20.62% |
| Revenue Growth (this year): | 20.35% | Revenue Growth (next year): | 17.42% |
Stock Insider Trading Activity of Harmony Biosciences Holdings Inc. (HRMY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kapadia Sandip | HRMY | CHIEF FINANCIAL OFFICER | Apr 1 '25 | Sell | $32.80 | 6,987 | $227,385.94 | 740 | |
| Dierks Jeffrey | HRMY | CHIEF COMMERCIAL OFFICER | Mar 3 '25 | Sell | $32.92 | 4,869 | $159,089.50 | 500 |
Latest Harmony Biosciences Holdings Inc. News
HRMY Breaking Stock News: Dive into HRMY Ticker-Specific Updates for Smart Investing
Argus Research
11 days ago
HRMY: Raising target price to $46.00
MT Newswires
16 days ago
Mizuho Raises Price Target on Harmony Biosciences to $48 From $44, Keeps Outperform Rating
Argus Research
18 days ago
HRMY: Raising target price to $45.00
Simply Wall St.
19 days ago
We Like Harmony Biosciences Holdings' (NASDAQ:HRMY) Earnings For More Than Just Statutory Profit
Simply Wall St.
24 days ago
Harmony Biosciences Holdings First Quarter 2025 Earnings: Beats Expectations
GuruFocus.com
25 days ago
Harmony Biosciences Holdings Inc (HRMY) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ...
Thomson Reuters StreetEvents
25 days ago
Q1 2025 Harmony Biosciences Holdings Inc Earnings Call
Argus Research
25 days ago
HRMY: Raising target price to $42.00
Compare HRMY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HRMY Harmony Biosciences Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.